Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to European Commission Approval of ILUMETRI, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, First USFDA approval for Sun Pharma's Halol plant after warnings
This speciality drug, Sun claimed, is the first and only form of latanoprost that is not formulated with benzalkonium chloride Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant S Sanghvi Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Family Investment Pvt Ltd Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to USFDA Approval of XELPROS, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on www.livemint.com - September 11, 2018 titled "Sun Pharma's Mohali plant on FDA radar"Sun Pharmaceutical Industries Ltd response is enclosed. Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on www.livemint.com - September 11, 2018 titled "Sun Pharma's Mohali plant on FDA radar".The reply is awaited. Sun Pharma arm to acquire shares of Israeli firm Tarsius Pharma
Drug major Sun Pharmaceutical Industries Monday said it has agreed to acquire 18.75 per cent shares of Israel-based Tarsius Pharma for a cash consid Announcement under Regulation 30 (LODR)-Acquisition
This is to inform you that one of the wholly owned subsidiaries of the Company has agreed to acquire shares of Tarsius Pharma Ltd, ('Tarsius'), Israel, by way of subscription of 345,622 ordinary shares of nominal value of NIS 0.01 each, representing 18.75% of shares of Tarsius, on a fully diluted basis. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of... Sun Pharma's Halol plant is in trouble yet again, gets USFDA observations
Halol, a key plant for the drug maker to manufacture injectables and specialty drugs, was under regulatory scanner since 2014